Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-08-30

Study Completion Date

2029-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is a single-arm, single-center Investigator-Initiated Trial (IIT) designed to evaluate the safety, pharmacokinetic profile, and preliminary efficacy of CD19-BCMA CAR-T cells in subjects diagnosed with connective tissue diseases.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

An Exploratory Study of CD19/CD22/BCMA CAR-T Cells (BZE2204) in Subjects With Relapsed or Refractory Autoimmune Diseases

NCT07174843

Idiopathic Inflammatory Myopathies(IIM) Immune Thrombocytopenia(ITP) Systemic Lupus Erythematosus(SLE)

RECRUITING EARLY_PHASE1

A Study of CD19/BCMA Chimeric Antigen Receptor T Cells Therapy for Patients With Refractory Scleroderma

NCT05085444

Scleroderma Autoimmune Diseases

UNKNOWN EARLY_PHASE1

CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C) in Patients With Relapse/Refractory Autoimmune Diseases

NCT07315087

SLE - Systemic Lupus Erythematosus SSc-Systemic Sclerosis IIM- Idiopathic Inflammatory Myopathies +3 more

RECRUITING PHASE1

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases

NCT06794008

Systemic Lupus Erythematosus Inflammatory Myopathy Systemic Sclerosis (SSc) +6 more

RECRUITING PHASE2

A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

NCT07203404

SLE LN ANCA Associated Vasculitis +5 more

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Connective Tissue Diseases

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

CAR-T

The dosage range of 1.0 × 10\^6/kg (± 20%) to 3.0 × 10\^6/kg (± 20%) of CAR-T cells, administered intravenously.

Group Type EXPERIMENTAL

CAR-T

Intervention Type BIOLOGICAL

Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CAR-T

Eligible subjects who successfully passed screening will receive CAR-T cell infusion on Day 0 after lymphodepleting preconditioning chemotherapy.

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Good compliance: The patient or their guardian understands and voluntarily signs the informed consent form, and it is expected that all documents, procedures, follow-up examinations and treatments stipulated in the study can be completed.
2. Previously diagnosed with one of the following diseases and meeting the corresponding latest international classification/diagnostic criteria :

1. Systemic lupus erythematosus (SLE);
2. Rheumatoid arthritis (RA);
3. Systemic scleroderma (SSc) ;
4. Sjogren's Syndrome (SS);
5. Polymyositis/dermatomyositis (PM/DM);
6. Mixed connective tissue disease (MCTD).
3. Researchers determine that the disease is in an active stage;
4. At least one autoantibody is positive in the serum or plasma during the screening period;
5. Insufficient response, intolerance or recurrence to at least one standard treatment;
6. The pregnancy test of the female subjects was negative, and the subjects agreed to take effective contraceptive measures throughout the trial period.
7. The patient's major tissues and organs are functioning well.

Exclusion Criteria

1. Intracranial hypertension or confusion;
2. Symptomatic heart failure or severe arrhythmia;
3. Respiratory failure;
4. Accompanied by other types of malignant tumors;
5. Diffuse vascular coagulation;
6. Serum creatinine and/or urea nitrogen ≥ 1.5 times the normal value;
7. Sepsis or other difficult-to-control infections;
8. Uncontrollable diabetes;
9. Severe mental disorder;
10. Cranial magnetic resonance imaging (MRI) examination revealed obvious lesions in the intracranial cavity.
11. WHO physical status classification ≥ level 3;
12. Organ transplant recipients;
13. Pregnant and lactating women;
14. HIV+，HBV，HCV，EBV，CMV.

Minimum Eligible Age

1 Year

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No